Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern poses a potential obstacle to achieving vaccine-induced immunity. Pegu et al . examined how viral variants, including the B.1.351 (Beta) and B.1.617.2 (Delta) variant, affected the immune response in a...
Saved in:
| Published in | Science (American Association for the Advancement of Science) Vol. 373; no. 6561; pp. 1372 - 1377 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
The American Association for the Advancement of Science
17.09.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern poses a potential obstacle to achieving vaccine-induced immunity. Pegu
et al
. examined how viral variants, including the B.1.351 (Beta) and B.1.617.2 (Delta) variant, affected the immune response in a small number of individuals who received the Moderna mRNA-1273 vaccine. By analyzing sera obtained 6 months after the second shot in the primary vaccine series, the researchers found that neutralizing antibody titers persisted against all variants tested. However, neutralizing antibodies against the B1.351 variant had dropped considerably by 6 months, and some individuals had weak, and in some cases no, neutralizing activity. These data may help to guide public health policies regarding additional booster vaccinations. —PNK
Most individuals vaccinated with mRNA-1273 develop functional antibodies against SARS-CoV-2 variants for at least 6 months.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations. |
|---|---|
| AbstractList | SARS-CoV-2 mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the impact of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and ACE2-competing antibodies elicited by the vaccine mRNA-1273 over seven months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6-months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations. A boost for boostersThe evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern poses a potential obstacle to achieving vaccine-induced immunity. Pegu et al. examined how viral variants, including the B.1.351 (Beta) and B.1.617.2 (Delta) variant, affected the immune response in a small number of individuals who received the Moderna mRNA-1273 vaccine. By analyzing sera obtained 6 months after the second shot in the primary vaccine series, the researchers found that neutralizing antibody titers persisted against all variants tested. However, neutralizing antibodies against the B1.351 variant had dropped considerably by 6 months, and some individuals had weak, and in some cases no, neutralizing activity. These data may help to guide public health policies regarding additional booster vaccinations. —PNKSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations. The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern poses a potential obstacle to achieving vaccine-induced immunity. Pegu et al . examined how viral variants, including the B.1.351 (Beta) and B.1.617.2 (Delta) variant, affected the immune response in a small number of individuals who received the Moderna mRNA-1273 vaccine. By analyzing sera obtained 6 months after the second shot in the primary vaccine series, the researchers found that neutralizing antibody titers persisted against all variants tested. However, neutralizing antibodies against the B1.351 variant had dropped considerably by 6 months, and some individuals had weak, and in some cases no, neutralizing activity. These data may help to guide public health policies regarding additional booster vaccinations. —PNK Most individuals vaccinated with mRNA-1273 develop functional antibodies against SARS-CoV-2 variants for at least 6 months. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations. |
| Author | Corbett, Kizzmekia S. Shi, Wei Winston, Juton Rostad, Christina A. Makhene, Mamodikoe Rebolledo, Paulina A. Rouphael, Nadine Carfi, Andrea Nguyen, Matthew Jackson, Lisa Roederer, Mario Elsafy, Mohammed Edupuganti, Srilatha Jackson, Lisa A. Beigel, John H. Anderson, Evan Kamidani, Satoshi Altaras, Nedim Emil McDermott, Adrian B. Anderson, Evan J. Hoang, Binh Nayak, Seema Lasicka, Susan O’Dell, Sijy Flach, Britta Ledgerwood, Julie E. Camacho-Gonzalez, Andres F. Phadke, Varun K. Roberts, Paul C. Teherani, Mehgan Lee, Stella Rouphael, Nadine G. Arega, Jae Makowski, Mat Benoit, Joyce Kunwar, Pratap Buchanan, Wendy Pimienta, Stephanie Luke, Catherine J. Edara, Venkata Viswanadh Peters, Etza Sherman, Amy Gibson, Theda Yang, Eun Sung Yildirim, Inci Fields, Colin Bennett, Hamilton Suthar, Mehul S. Lai, Lilin Carste, Barbara Kelley, Colleen Ackerley, Cassie M. Grimsley Stephens, Kathy Graham, Barney S. Scherer, Erin Suyehira, Janice Kao, Carol Schmidt, Stephen D. Kolhekar, Aparna Collins, Matthew Albert, Jim Pikaart-Tautges, Rhonda Erolin, Roxanne Lampley, |
| AuthorAffiliation | 6 Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA 3 Emmes Company, Rockville, MD 20850, USA 7 Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur, GA 30030, USA 2 Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA 1 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA 5 Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA 4 Moderna, Inc., Cambridge, MA 02139, USA |
| AuthorAffiliation_xml | – name: 1 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – name: 5 Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA – name: 7 Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur, GA 30030, USA – name: 6 Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – name: 2 Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – name: 3 Emmes Company, Rockville, MD 20850, USA – name: 4 Moderna, Inc., Cambridge, MA 02139, USA |
| Author_xml | – sequence: 1 givenname: Amarendra orcidid: 0000-0003-3564-6453 surname: Pegu fullname: Pegu, Amarendra organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 2 givenname: Sarah E. surname: O’Connell fullname: O’Connell, Sarah E. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 3 givenname: Stephen D. orcidid: 0000-0002-7284-3870 surname: Schmidt fullname: Schmidt, Stephen D. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 4 givenname: Sijy surname: O’Dell fullname: O’Dell, Sijy organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 5 givenname: Chloe A. orcidid: 0000-0002-0313-8502 surname: Talana fullname: Talana, Chloe A. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 6 givenname: Lilin surname: Lai fullname: Lai, Lilin organization: Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 7 givenname: Jim surname: Albert fullname: Albert, Jim organization: Emmes Company, Rockville, MD 20850, USA – sequence: 8 givenname: Evan orcidid: 0000-0002-1576-4420 surname: Anderson fullname: Anderson, Evan organization: Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 9 givenname: Hamilton surname: Bennett fullname: Bennett, Hamilton organization: Moderna, Inc., Cambridge, MA 02139, USA – sequence: 10 givenname: Kizzmekia S. orcidid: 0000-0002-2641-4688 surname: Corbett fullname: Corbett, Kizzmekia S. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 11 givenname: Britta surname: Flach fullname: Flach, Britta organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 12 givenname: Lisa orcidid: 0000-0002-1785-0218 surname: Jackson fullname: Jackson, Lisa organization: Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA – sequence: 13 givenname: Brett surname: Leav fullname: Leav, Brett organization: Moderna, Inc., Cambridge, MA 02139, USA – sequence: 14 givenname: Julie E. surname: Ledgerwood fullname: Ledgerwood, Julie E. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 15 givenname: Catherine J. surname: Luke fullname: Luke, Catherine J. organization: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 16 givenname: Mat surname: Makowski fullname: Makowski, Mat organization: Emmes Company, Rockville, MD 20850, USA – sequence: 17 givenname: Martha C. orcidid: 0000-0002-0110-881X surname: Nason fullname: Nason, Martha C. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 18 givenname: Paul C. orcidid: 0000-0002-4452-141X surname: Roberts fullname: Roberts, Paul C. organization: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 19 givenname: Mario orcidid: 0000-0001-7448-7040 surname: Roederer fullname: Roederer, Mario organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 20 givenname: Paulina A. orcidid: 0000-0002-9808-063X surname: Rebolledo fullname: Rebolledo, Paulina A. organization: Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur, GA 30030, USA – sequence: 21 givenname: Christina A. orcidid: 0000-0001-8439-0592 surname: Rostad fullname: Rostad, Christina A. organization: Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 22 givenname: Nadine G. orcidid: 0000-0002-2512-7919 surname: Rouphael fullname: Rouphael, Nadine G. organization: Hope Clinic, Department of Medicine, Emory University School of Medicine, Decatur, GA 30030, USA – sequence: 23 givenname: Wei surname: Shi fullname: Shi, Wei organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 24 givenname: Lingshu orcidid: 0000-0002-8404-4910 surname: Wang fullname: Wang, Lingshu organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 25 givenname: Alicia T. orcidid: 0000-0001-7615-8320 surname: Widge fullname: Widge, Alicia T. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 26 givenname: Eun Sung orcidid: 0000-0003-3161-1624 surname: Yang fullname: Yang, Eun Sung organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 27 givenname: John H. orcidid: 0000-0002-4879-4941 surname: Beigel fullname: Beigel, John H. organization: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 28 givenname: Barney S. orcidid: 0000-0001-8112-0853 surname: Graham fullname: Graham, Barney S. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 29 givenname: John R. orcidid: 0000-0002-5293-4695 surname: Mascola fullname: Mascola, John R. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 30 givenname: Mehul S. orcidid: 0000-0002-2686-8380 surname: Suthar fullname: Suthar, Mehul S. organization: Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA – sequence: 31 givenname: Adrian B. orcidid: 0000-0003-0616-9117 surname: McDermott fullname: McDermott, Adrian B. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 32 givenname: Nicole A. orcidid: 0000-0002-5731-3054 surname: Doria-Rose fullname: Doria-Rose, Nicole A. organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA – sequence: 33 givenname: Jae surname: Arega fullname: Arega, Jae – sequence: 34 givenname: John H. surname: Beigel fullname: Beigel, John H. – sequence: 35 givenname: Wendy surname: Buchanan fullname: Buchanan, Wendy – sequence: 36 givenname: Mohammed surname: Elsafy fullname: Elsafy, Mohammed – sequence: 37 givenname: Binh surname: Hoang fullname: Hoang, Binh – sequence: 38 givenname: Rebecca surname: Lampley fullname: Lampley, Rebecca – sequence: 39 givenname: Aparna surname: Kolhekar fullname: Kolhekar, Aparna – sequence: 40 givenname: Hyung surname: Koo fullname: Koo, Hyung – sequence: 41 givenname: Catherine surname: Luke fullname: Luke, Catherine – sequence: 42 givenname: Mamodikoe surname: Makhene fullname: Makhene, Mamodikoe – sequence: 43 givenname: Seema surname: Nayak fullname: Nayak, Seema – sequence: 44 givenname: Rhonda surname: Pikaart-Tautges fullname: Pikaart-Tautges, Rhonda – sequence: 45 givenname: Paul C. surname: Roberts fullname: Roberts, Paul C. – sequence: 46 givenname: Janie surname: Russell fullname: Russell, Janie – sequence: 47 givenname: Elisa surname: Sindall fullname: Sindall, Elisa – sequence: 48 givenname: Jim surname: Albert fullname: Albert, Jim – sequence: 49 givenname: Pratap surname: Kunwar fullname: Kunwar, Pratap – sequence: 50 givenname: Mat surname: Makowski fullname: Makowski, Mat – sequence: 51 givenname: Evan J. surname: Anderson fullname: Anderson, Evan J. – sequence: 52 givenname: Amer surname: Bechnak fullname: Bechnak, Amer – sequence: 53 givenname: Mary surname: Bower fullname: Bower, Mary – sequence: 54 givenname: Andres F. surname: Camacho-Gonzalez fullname: Camacho-Gonzalez, Andres F. – sequence: 55 givenname: Matthew surname: Collins fullname: Collins, Matthew – sequence: 56 givenname: Ana surname: Drobeniuc fullname: Drobeniuc, Ana – sequence: 57 givenname: Venkata Viswanadh surname: Edara fullname: Edara, Venkata Viswanadh – sequence: 58 givenname: Srilatha surname: Edupuganti fullname: Edupuganti, Srilatha – sequence: 59 givenname: Katharine surname: Floyd fullname: Floyd, Katharine – sequence: 60 givenname: Theda surname: Gibson fullname: Gibson, Theda – sequence: 61 givenname: Cassie M. Grimsley surname: Ackerley fullname: Ackerley, Cassie M. Grimsley – sequence: 62 givenname: Brandi surname: Johnson fullname: Johnson, Brandi – sequence: 63 givenname: Satoshi surname: Kamidani fullname: Kamidani, Satoshi – sequence: 64 givenname: Carol surname: Kao fullname: Kao, Carol – sequence: 65 givenname: Colleen surname: Kelley fullname: Kelley, Colleen – sequence: 66 givenname: Lilin surname: Lai fullname: Lai, Lilin – sequence: 67 givenname: Hollie surname: Macenczak fullname: Macenczak, Hollie – sequence: 68 givenname: Michele Paine surname: McCullough fullname: McCullough, Michele Paine – sequence: 69 givenname: Etza surname: Peters fullname: Peters, Etza – sequence: 70 givenname: Varun K. surname: Phadke fullname: Phadke, Varun K. – sequence: 71 givenname: Paulina A. surname: Rebolledo fullname: Rebolledo, Paulina A. – sequence: 72 givenname: Christina A. surname: Rostad fullname: Rostad, Christina A. – sequence: 73 givenname: Nadine surname: Rouphael fullname: Rouphael, Nadine – sequence: 74 givenname: Erin surname: Scherer fullname: Scherer, Erin – sequence: 75 givenname: Amy surname: Sherman fullname: Sherman, Amy – sequence: 76 givenname: Kathy surname: Stephens fullname: Stephens, Kathy – sequence: 77 givenname: Mehul S. surname: Suthar fullname: Suthar, Mehul S. – sequence: 78 givenname: Mehgan surname: Teherani fullname: Teherani, Mehgan – sequence: 79 givenname: Jessica surname: Traenkner fullname: Traenkner, Jessica – sequence: 80 givenname: Juton surname: Winston fullname: Winston, Juton – sequence: 81 givenname: Inci surname: Yildirim fullname: Yildirim, Inci – sequence: 82 givenname: Lee surname: Barr fullname: Barr, Lee – sequence: 83 givenname: Joyce surname: Benoit fullname: Benoit, Joyce – sequence: 84 givenname: Barbara surname: Carste fullname: Carste, Barbara – sequence: 85 givenname: Joe surname: Choe fullname: Choe, Joe – sequence: 86 givenname: Maya surname: Dunstan fullname: Dunstan, Maya – sequence: 87 givenname: Roxanne surname: Erolin fullname: Erolin, Roxanne – sequence: 88 givenname: Jana surname: ffitch fullname: ffitch, Jana – sequence: 89 givenname: Colin surname: Fields fullname: Fields, Colin – sequence: 90 givenname: Lisa A. surname: Jackson fullname: Jackson, Lisa A. – sequence: 91 givenname: Erika surname: Kiniry fullname: Kiniry, Erika – sequence: 92 givenname: Susan surname: Lasicka fullname: Lasicka, Susan – sequence: 93 givenname: Stella surname: Lee fullname: Lee, Stella – sequence: 94 givenname: Matthew surname: Nguyen fullname: Nguyen, Matthew – sequence: 95 givenname: Stephanie surname: Pimienta fullname: Pimienta, Stephanie – sequence: 96 givenname: Janice surname: Suyehira fullname: Suyehira, Janice – sequence: 97 givenname: Michael surname: Witte fullname: Witte, Michael – sequence: 98 givenname: Hamilton surname: Bennett fullname: Bennett, Hamilton – sequence: 99 givenname: Nedim Emil surname: Altaras fullname: Altaras, Nedim Emil – sequence: 100 givenname: Andrea surname: Carfi fullname: Carfi, Andrea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34385356$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kctOHDEQRS1EBMNjzS5qiU02DXZ7_NogjSYJiYQSxGtrVdtu4lGPTexuJHb5h_xhvgSPGBBBYlWLOvfqVt0dtBlicAgdEHxESMOPs_EuGHcE7WJKBN9AE4IVq1WD6SaaYEx5LbFg22gn5wXGZafoFtqmUyoZZXyCzj-PCVrf--Ghil21vPgxq0kjaHUPxvjg_v3564MdjbMVhMG30XqXK7gFH_JQXc4uLut5vKmbwidfiLyHPnTQZ7e_nrvo-uuXq_m3-uzn6ff57Kw2jLChZtJiSoBxUMCwEVzQjhlcQgmJLXPEKo6NYa2zogWuWiAOy05aBbYBZekuOnnyvRvbpbPGhSFBr--SX0J60BG8_n8T_C99G--15IqwpikGn9YGKf4eXR700mfj-h6Ci2PWDeNkWr4kaEEP36CLOKZQzltRWAolpyvDj68TvUR5fnYB2BNgUsw5uU4bP8Dg4yqg7zXBelWqXpeq16UW3fEb3bP1e4pHfLynrw |
| CitedBy_id | crossref_primary_10_7554_eLife_89999_4 crossref_primary_10_20965_jdr_2022_p0007 crossref_primary_10_1038_s41590_024_01951_5 crossref_primary_10_3389_fimmu_2021_793953 crossref_primary_10_2139_ssrn_4059223 crossref_primary_10_1038_s41541_024_00870_8 crossref_primary_10_1080_22221751_2022_2081616 crossref_primary_10_1093_jmcb_mjac041 crossref_primary_10_1016_j_ebiom_2023_104842 crossref_primary_10_3389_fimmu_2022_833085 crossref_primary_10_1016_j_celrep_2024_113887 crossref_primary_10_1016_j_medj_2021_12_005 crossref_primary_10_2139_ssrn_3988003 crossref_primary_10_1016_j_ejca_2021_12_011 crossref_primary_10_1371_journal_pone_0268389 crossref_primary_10_3390_vaccines10071057 crossref_primary_10_1172_JCI157707 crossref_primary_10_1016_j_hsr_2022_100040 crossref_primary_10_1016_j_smim_2024_101884 crossref_primary_10_1542_peds_2022_056288 crossref_primary_10_1126_science_abl8912 crossref_primary_10_3390_vaccines13010030 crossref_primary_10_3390_vaccines12010081 crossref_primary_10_1016_j_medj_2021_12_002 crossref_primary_10_1126_science_abj9853 crossref_primary_10_1200_JCO_22_00088 crossref_primary_10_3389_fimmu_2022_967051 crossref_primary_10_1128_mbio_00902_23 crossref_primary_10_3390_ijms23147675 crossref_primary_10_1128_jvi_01571_23 crossref_primary_10_1093_cid_ciac796 crossref_primary_10_3389_fimmu_2021_789905 crossref_primary_10_1111_1753_0407_13448 crossref_primary_10_1016_j_nantod_2024_102586 crossref_primary_10_1038_s41467_024_50376_z crossref_primary_10_1016_j_talanta_2022_123498 crossref_primary_10_2807_1560_7917_ES_2023_28_47_2300187 crossref_primary_10_2139_ssrn_3991627 crossref_primary_10_1128_jvi_00582_22 crossref_primary_10_1038_s41598_022_13819_5 crossref_primary_10_3389_fmicb_2024_1488106 crossref_primary_10_3390_v14040653 crossref_primary_10_1016_S2665_9913_22_00191_6 crossref_primary_10_1111_1751_7915_13974 crossref_primary_10_1001_jamanetworkopen_2022_26335 crossref_primary_10_1002_btm2_10293 crossref_primary_10_1002_jmv_28642 crossref_primary_10_1016_j_idc_2022_01_004 crossref_primary_10_1038_s41590_022_01313_z crossref_primary_10_1038_s41581_021_00499_z crossref_primary_10_1002_jmv_27555 crossref_primary_10_1002_art_42372 crossref_primary_10_1093_jmcb_mjac023 crossref_primary_10_1128_spectrum_05353_22 crossref_primary_10_1016_j_vaccine_2023_08_042 crossref_primary_10_1001_jamanetworkopen_2021_43346 crossref_primary_10_1016_j_cell_2022_05_022 crossref_primary_10_4236_jbm_2022_1010006 crossref_primary_10_1016_j_celrep_2022_110394 crossref_primary_10_1126_scitranslmed_add6383 crossref_primary_10_1111_nyas_14975 crossref_primary_10_1126_sciimmunol_abn8590 crossref_primary_10_3390_ijms25031516 crossref_primary_10_1093_cid_ciac780 crossref_primary_10_1093_pnasnexus_pgac105 crossref_primary_10_1128_spectrum_04081_22 crossref_primary_10_1093_ofid_ofac677 crossref_primary_10_3390_vaccines11020314 crossref_primary_10_3390_vaccines11121739 crossref_primary_10_1093_infdis_jiac188 crossref_primary_10_1093_infdis_jiac065 crossref_primary_10_1016_j_actbio_2024_05_048 crossref_primary_10_3389_fimmu_2023_1196988 crossref_primary_10_1146_annurev_med_042420_112725 crossref_primary_10_3390_vaccines10020285 crossref_primary_10_3390_v15051146 crossref_primary_10_1016_j_jemep_2022_100761 crossref_primary_10_3390_biom12121742 crossref_primary_10_1038_s41598_023_46223_8 crossref_primary_10_1016_j_scib_2024_02_041 crossref_primary_10_1038_s41579_022_00822_w crossref_primary_10_1080_21645515_2023_2215677 crossref_primary_10_1111_bjh_18456 crossref_primary_10_1371_journal_pone_0277846 crossref_primary_10_1371_journal_pgph_0000412 crossref_primary_10_2139_ssrn_4127957 crossref_primary_10_1016_j_antiviral_2023_105556 crossref_primary_10_3390_v14020312 crossref_primary_10_3389_fimmu_2023_1055457 crossref_primary_10_1080_21645515_2022_2135927 crossref_primary_10_1016_j_ijid_2021_12_343 crossref_primary_10_1002_jcla_24731 crossref_primary_10_3390_vaccines10020291 crossref_primary_10_1016_j_virusres_2022_198765 crossref_primary_10_3390_vaccines11050920 crossref_primary_10_3390_vaccines12070742 crossref_primary_10_3390_vaccines10081217 crossref_primary_10_1002_iid3_1353 crossref_primary_10_3390_cells11121918 crossref_primary_10_3390_vaccines11030513 crossref_primary_10_3389_fimmu_2021_740708 crossref_primary_10_1038_s41598_023_40338_8 crossref_primary_10_1016_j_accpm_2021_100959 crossref_primary_10_1038_s41541_024_00997_8 crossref_primary_10_1016_j_intimp_2023_109968 crossref_primary_10_1038_s41586_022_04447_0 crossref_primary_10_15252_embr_202357724 crossref_primary_10_1002_jmv_28428 crossref_primary_10_1016_j_antiviral_2023_105789 crossref_primary_10_1080_21645515_2024_2425147 crossref_primary_10_1089_vim_2021_0121 crossref_primary_10_1038_s41467_022_31693_7 crossref_primary_10_3390_jcm14010289 crossref_primary_10_1186_s12979_022_00288_7 crossref_primary_10_1016_j_celrep_2022_110336 crossref_primary_10_1126_sciimmunol_abp8328 crossref_primary_10_3389_fpubh_2022_945448 crossref_primary_10_1177_2632010X231218075 crossref_primary_10_1016_j_micinf_2022_105044 crossref_primary_10_1056_NEJMra2206573 crossref_primary_10_1002_biot_202300130 crossref_primary_10_4103_ijmr_ijmr_2544_21 crossref_primary_10_1093_pnasnexus_pgac091 crossref_primary_10_1371_journal_ppat_1011057 crossref_primary_10_1172_jci_insight_157963 crossref_primary_10_3389_fimmu_2024_1385135 crossref_primary_10_1126_scitranslmed_abq4130 crossref_primary_10_3389_fimmu_2023_1107803 crossref_primary_10_3390_vaccines12010015 crossref_primary_10_3390_vaccines9101108 crossref_primary_10_1002_ajh_26380 crossref_primary_10_3389_fviro_2022_891540 crossref_primary_10_1016_j_vaccine_2023_11_059 crossref_primary_10_1038_s41598_022_25134_0 crossref_primary_10_1038_s41591_023_02517_y crossref_primary_10_3389_fimmu_2022_990071 crossref_primary_10_1128_spectrum_01402_21 crossref_primary_10_5005_jp_journals_11005_0027 crossref_primary_10_1126_sciimmunol_abo0226 crossref_primary_10_3390_vaccines10071068 crossref_primary_10_1002_jmv_27596 crossref_primary_10_1016_j_exphem_2023_11_002 crossref_primary_10_3389_fimmu_2022_908478 crossref_primary_10_3390_vaccines12050478 crossref_primary_10_1038_s41392_023_01447_y crossref_primary_10_1016_j_jim_2022_113351 crossref_primary_10_7554_eLife_83641 crossref_primary_10_1021_acsnano_2c02794 crossref_primary_10_3390_life12122064 crossref_primary_10_1080_1744666X_2022_2044797 crossref_primary_10_1186_s41232_023_00255_9 crossref_primary_10_5858_arpa_2023_0014_OA crossref_primary_10_1056_NEJMc2115596 crossref_primary_10_3389_fimmu_2024_1383086 crossref_primary_10_1155_bmri_3420875 crossref_primary_10_2215_CJN_12250921 crossref_primary_10_1093_nar_gkab764 crossref_primary_10_1038_s41541_023_00724_9 crossref_primary_10_1017_S0950268823000821 crossref_primary_10_3390_vaccines11071183 crossref_primary_10_1093_infdis_jiac421 crossref_primary_10_1186_s12879_024_09861_5 crossref_primary_10_1038_s41590_021_01021_0 crossref_primary_10_7554_eLife_89999 crossref_primary_10_1016_j_jiac_2024_03_021 crossref_primary_10_1097_HS9_0000000000000677 crossref_primary_10_3390_microorganisms11030717 crossref_primary_10_1038_s41392_021_00796_w crossref_primary_10_1371_journal_pone_0272298 crossref_primary_10_1038_s41467_023_39189_8 crossref_primary_10_1038_s44286_024_00116_3 crossref_primary_10_3390_pathogens12050688 crossref_primary_10_3390_vaccines10050709 crossref_primary_10_1038_s41591_022_01679_5 crossref_primary_10_54724_lc_2022_e5 crossref_primary_10_1371_journal_pone_0267566 crossref_primary_10_7554_eLife_78633 crossref_primary_10_1038_s41541_022_00586_7 crossref_primary_10_1038_s41541_022_00540_7 crossref_primary_10_1038_s42003_022_04216_9 crossref_primary_10_1001_jamanetworkopen_2022_14171 crossref_primary_10_1002_jmv_28102 crossref_primary_10_1016_j_xcrm_2022_100529 crossref_primary_10_1016_j_resinv_2022_11_005 crossref_primary_10_1126_scitranslmed_adn6605 crossref_primary_10_1172_jci_insight_157031 crossref_primary_10_3389_fddsv_2022_858006 crossref_primary_10_3390_diseases12010016 crossref_primary_10_1001_jamaoncol_2022_0446 crossref_primary_10_1016_j_jiph_2023_10_007 crossref_primary_10_3390_v14050961 crossref_primary_10_1016_j_xcrm_2022_100520 crossref_primary_10_1080_14760584_2022_1997601 crossref_primary_10_1126_scitranslmed_adn2364 crossref_primary_10_1038_s41422_022_00612_2 crossref_primary_10_1080_21645515_2022_2060018 crossref_primary_10_1136_bmj_2021_069052 crossref_primary_10_1038_s41467_022_35456_2 crossref_primary_10_1136_bmjopen_2022_061345 crossref_primary_10_3390_vaccines10010064 crossref_primary_10_2139_ssrn_4065610 crossref_primary_10_1038_s41467_022_29477_0 crossref_primary_10_1038_s41467_022_31929_6 crossref_primary_10_1038_s41576_021_00408_x crossref_primary_10_1007_s12038_023_00355_1 crossref_primary_10_1097_TXD_0000000000001645 crossref_primary_10_3389_fimmu_2024_1285278 crossref_primary_10_1016_j_heliyon_2023_e16349 crossref_primary_10_1016_j_xcrm_2022_100634 crossref_primary_10_1183_23120541_00400_2023 crossref_primary_10_1111_risa_17699 crossref_primary_10_1016_j_ebiom_2023_104563 crossref_primary_10_3389_fimmu_2023_1241038 crossref_primary_10_1016_j_celrep_2023_112402 crossref_primary_10_3389_fimmu_2022_947602 crossref_primary_10_1016_j_vaccine_2023_02_017 crossref_primary_10_3389_fviro_2024_1479645 crossref_primary_10_3390_life11101077 crossref_primary_10_1042_BST20220415 crossref_primary_10_1136_bmj_2021_068848 crossref_primary_10_1080_22221751_2022_2149353 crossref_primary_10_1093_intimm_dxac031 crossref_primary_10_3389_fimmu_2021_815404 crossref_primary_10_3390_diagnostics12010085 crossref_primary_10_1016_j_anai_2022_06_009 crossref_primary_10_1016_j_heliyon_2022_e09863 crossref_primary_10_1053_j_ajkd_2021_10_003 crossref_primary_10_3390_vaccines11040806 crossref_primary_10_1186_s12986_022_00717_w crossref_primary_10_1038_s41577_022_00813_1 crossref_primary_10_1186_s43556_024_00232_9 crossref_primary_10_1038_s41591_023_02582_3 crossref_primary_10_1002_mco2_167 crossref_primary_10_1016_j_amc_2023_127905 crossref_primary_10_1038_s41598_024_61922_6 crossref_primary_10_1056_NEJMc2119912 crossref_primary_10_3390_vaccines11050969 crossref_primary_10_1126_scitranslmed_abn6150 crossref_primary_10_1016_j_ymthe_2022_05_007 crossref_primary_10_1038_d41586_021_02532_4 crossref_primary_10_1111_apm_13215 crossref_primary_10_1038_s41541_022_00575_w crossref_primary_10_1038_s41598_023_32021_9 crossref_primary_10_1126_science_add2897 crossref_primary_10_1016_j_vaccine_2024_05_058 crossref_primary_10_3390_vaccines10020327 crossref_primary_10_1038_s41591_022_01705_6 crossref_primary_10_1042_BST20210859 crossref_primary_10_1038_s41408_023_00824_8 crossref_primary_10_1177_20587384211050199 crossref_primary_10_3389_fimmu_2023_1183727 crossref_primary_10_1007_s00705_023_05815_5 crossref_primary_10_1016_j_biopha_2022_113522 crossref_primary_10_1016_j_isci_2022_105209 crossref_primary_10_1021_acs_jproteome_2c00514 crossref_primary_10_1128_spectrum_00211_22 crossref_primary_10_1080_1744666X_2022_2074403 crossref_primary_10_1016_j_ijid_2022_01_068 crossref_primary_10_1080_21645515_2023_2190690 crossref_primary_10_1016_j_jiac_2022_03_021 crossref_primary_10_1038_s41421_022_00373_7 crossref_primary_10_3390_children9101467 crossref_primary_10_1038_s41541_023_00693_z crossref_primary_10_1111_imr_13089 crossref_primary_10_1126_sciadv_abq8276 crossref_primary_10_1016_j_vaccine_2022_08_037 crossref_primary_10_3389_fimmu_2021_744242 crossref_primary_10_1007_s11427_023_2378_x crossref_primary_10_3389_fimmu_2023_1100594 crossref_primary_10_1002_rmv_2346 crossref_primary_10_1093_cid_ciac498 crossref_primary_10_1111_all_15252 crossref_primary_10_1016_j_annepidem_2022_08_051 crossref_primary_10_1016_j_vaccine_2023_01_032 crossref_primary_10_3390_vaccines10060905 crossref_primary_10_1016_j_vaccine_2022_05_047 crossref_primary_10_1016_j_cmi_2021_10_005 crossref_primary_10_1128_spectrum_02747_22 crossref_primary_10_3390_vaccines10010099 crossref_primary_10_1038_s41590_022_01130_4 crossref_primary_10_1056_NEJMoa2116414 crossref_primary_10_3389_fimmu_2022_949248 crossref_primary_10_3390_pharmaceutics14122653 crossref_primary_10_3390_vaccines11040832 crossref_primary_10_1007_s40120_021_00288_7 crossref_primary_10_1038_s41564_021_01051_2 crossref_primary_10_3390_vaccines10101708 crossref_primary_10_1038_s41541_024_00835_x crossref_primary_10_3389_fbioe_2022_867119 crossref_primary_10_1016_j_jim_2022_113410 crossref_primary_10_1126_scitranslmed_abn7842 crossref_primary_10_1016_j_vaccine_2023_06_017 crossref_primary_10_1038_s41467_022_30864_w crossref_primary_10_1111_imr_13115 crossref_primary_10_1186_s12916_023_02942_3 crossref_primary_10_1093_clinchem_hvab283 crossref_primary_10_1016_j_coph_2022_102243 crossref_primary_10_1016_j_mayocp_2021_10_011 crossref_primary_10_1016_j_anrea_2022_02_001 crossref_primary_10_1177_00333549221123579 crossref_primary_10_3389_fimmu_2022_975533 crossref_primary_10_3390_v14010104 crossref_primary_10_1016_j_xcrm_2023_101134 crossref_primary_10_1111_tid_13748 crossref_primary_10_3390_vaccines10071137 crossref_primary_10_1007_s40121_022_00753_2 crossref_primary_10_1126_sciimmunol_ado5937 crossref_primary_10_3390_v16030407 crossref_primary_10_1128_spectrum_02257_22 crossref_primary_10_1128_jvi_01973_21 crossref_primary_10_3390_v14020380 crossref_primary_10_1016_j_yexcr_2023_113853 crossref_primary_10_1038_s41541_023_00707_w crossref_primary_10_1097_MRM_0000000000000393 crossref_primary_10_3390_vaccines10020225 crossref_primary_10_1080_22221751_2022_2122580 crossref_primary_10_3390_biomedicines9111714 crossref_primary_10_3390_vaccines11111720 crossref_primary_10_1056_NEJMoa2208343 crossref_primary_10_1186_s12916_022_02570_3 crossref_primary_10_3390_cells11010067 crossref_primary_10_3390_v14020389 crossref_primary_10_3390_vaccines10040608 crossref_primary_10_1002_cti2_1463 crossref_primary_10_1038_s41392_023_01345_3 crossref_primary_10_1038_s42003_022_03893_w crossref_primary_10_3390_diagnostics12010205 crossref_primary_10_1038_s41541_023_00679_x crossref_primary_10_1080_14760584_2022_2141711 crossref_primary_10_1093_bib_bbad339 crossref_primary_10_1111_jcmm_17186 crossref_primary_10_3389_fpubh_2025_1478627 crossref_primary_10_3390_vaccines11040719 crossref_primary_10_1038_s41467_023_39053_9 crossref_primary_10_1021_acsinfecdis_1c00600 crossref_primary_10_3389_fmed_2022_811004 crossref_primary_10_3389_fimmu_2023_1188392 crossref_primary_10_33442_vt202107 crossref_primary_10_1016_j_xcrm_2022_100793 crossref_primary_10_1126_scitranslmed_abm3302 crossref_primary_10_3390_microorganisms11071628 crossref_primary_10_1016_j_celrep_2023_112326 crossref_primary_10_1084_jem_20220258 crossref_primary_10_3389_fimmu_2023_1129753 crossref_primary_10_1016_S1473_3099_22_00028_7 crossref_primary_10_1128_spectrum_01316_23 crossref_primary_10_3389_fimmu_2021_798389 crossref_primary_10_3390_pathogens14010044 crossref_primary_10_1016_j_tmaid_2022_102514 crossref_primary_10_1073_pnas_2204607119 crossref_primary_10_1016_S2666_5247_22_00027_1 crossref_primary_10_1016_j_jtbi_2023_111522 crossref_primary_10_2139_ssrn_4111432 crossref_primary_10_1038_s41467_023_40960_0 crossref_primary_10_1016_j_molmed_2022_04_007 crossref_primary_10_3390_jdb9040054 crossref_primary_10_1016_j_clim_2023_109809 crossref_primary_10_1016_j_idm_2023_07_002 crossref_primary_10_2147_JMDH_S347669 crossref_primary_10_1016_j_vaccine_2023_02_050 crossref_primary_10_1172_JCI167955 crossref_primary_10_1371_journal_pone_0268767 crossref_primary_10_2139_ssrn_4126595 crossref_primary_10_1038_s41467_023_38892_w crossref_primary_10_3390_vaccines12111284 crossref_primary_10_1093_ofid_ofad288 crossref_primary_10_1038_s41598_021_03978_2 crossref_primary_10_3390_vaccines11020354 crossref_primary_10_1002_art_42109 crossref_primary_10_1038_s41586_022_04690_5 crossref_primary_10_1016_j_heliyon_2024_e28405 crossref_primary_10_3390_pharmaceutics15051412 crossref_primary_10_7554_eLife_80428 crossref_primary_10_1038_s41467_023_36908_z crossref_primary_10_1038_s41591_022_02031_7 crossref_primary_10_1080_21645515_2022_2094142 crossref_primary_10_1186_s12985_023_02279_6 crossref_primary_10_3390_tropicalmed7050066 crossref_primary_10_12688_f1000research_109676_1 crossref_primary_10_3389_fimmu_2022_882515 crossref_primary_10_1016_j_jaci_2023_10_012 crossref_primary_10_12688_f1000research_109676_2 |
| Cites_doi | 10.1056/NEJMoa2101765 10.1056/NEJMoa2022483 10.1101/2021.05.05.21256716 10.1002/cpim.116 10.1056/NEJMoa2028436 10.1001/jama.2021.4388 10.1056/NEJMoa2035389 10.1038/s41591-021-01285-x 10.1016/j.celrep.2021.109017 10.1056/NEJMc2104974 10.1038/s41422-021-00496-8 10.1016/j.smim.2018.10.010 10.1038/s41586-021-03696-9 10.1016/j.jbc.2021.100536 10.1056/NEJMc2108829 10.1056/NEJMc2032195 10.1016/j.cell.2021.03.036 10.1056/NEJMc2102179 10.1126/science.abh1766 10.1016/j.chom.2021.03.009 10.1038/s41586-021-03398-2 10.1371/journal.pntd.0006862 10.1056/NEJMc2103740 10.1016/j.chom.2020.11.012 10.1101/2021.02.18.431897 10.1073/pnas.93.21.11382 10.1056/NEJMoa2001017 10.1056/NEJMc2103916 10.1126/science.abb2507 10.1016/S0140-6736(21)01358-1 10.1128/JVI.01118-06 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). |
| Copyright_xml | – notice: Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). |
| CorporateAuthor | The mRNA-1273 Study Group mRNA-1273 Study Group |
| CorporateAuthor_xml | – name: The mRNA-1273 Study Group – name: mRNA-1273 Study Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QF 7QG 7QL 7QP 7QQ 7QR 7SC 7SE 7SN 7SP 7SR 7SS 7T7 7TA 7TB 7TK 7TM 7U5 7U9 8BQ 8FD C1K F28 FR3 H8D H8G H94 JG9 JQ2 K9. KR7 L7M L~C L~D M7N P64 RC3 7X8 5PM |
| DOI | 10.1126/science.abj4176 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Aluminium Industry Abstracts Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Ceramic Abstracts Chemoreception Abstracts Computer and Information Systems Abstracts Corrosion Abstracts Ecology Abstracts Electronics & Communications Abstracts Engineered Materials Abstracts Entomology Abstracts (Full archive) Industrial and Applied Microbiology Abstracts (Microbiology A) Materials Business File Mechanical & Transportation Engineering Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Solid State and Superconductivity Abstracts Virology and AIDS Abstracts METADEX Technology Research Database Environmental Sciences and Pollution Management ANTE: Abstracts in New Technology & Engineering Engineering Research Database Aerospace Database Copper Technical Reference Library AIDS and Cancer Research Abstracts Materials Research Database ProQuest Computer Science Collection ProQuest Health & Medical Complete (Alumni) Civil Engineering Abstracts Advanced Technologies Database with Aerospace Computer and Information Systems Abstracts Academic Computer and Information Systems Abstracts Professional Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Materials Research Database Technology Research Database Computer and Information Systems Abstracts – Academic Mechanical & Transportation Engineering Abstracts Nucleic Acids Abstracts ProQuest Computer Science Collection Computer and Information Systems Abstracts ProQuest Health & Medical Complete (Alumni) Materials Business File Environmental Sciences and Pollution Management Aerospace Database Copper Technical Reference Library Engineered Materials Abstracts Genetics Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Advanced Technologies Database with Aerospace ANTE: Abstracts in New Technology & Engineering Civil Engineering Abstracts Aluminium Industry Abstracts Virology and AIDS Abstracts Electronics & Communications Abstracts Ceramic Abstracts Ecology Abstracts Neurosciences Abstracts METADEX Biotechnology and BioEngineering Abstracts Computer and Information Systems Abstracts Professional Entomology Abstracts Animal Behavior Abstracts Solid State and Superconductivity Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Corrosion Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Materials Research Database MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Biology Public Health |
| EISSN | 1095-9203 |
| EndPage | 1377 |
| ExternalDocumentID | PMC8691522 34385356 10_1126_science_abj4176 |
| Genre | Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: HHSN272201500002C – fundername: NIAID NIH HHS grantid: UM1 AI148576 – fundername: NIAID NIH HHS grantid: UM1 AI148373 – fundername: NIAID NIH HHS grantid: R21 AI158788 – fundername: NIAID NIH HHS grantid: UM1 AI148684 – fundername: NCATS NIH HHS grantid: UL1 TR001863 – fundername: Intramural NIH HHS grantid: Z99 AI999999 – fundername: NIAID NIH HHS grantid: U01 AI151698 – fundername: NIH HHS grantid: P51 OD011132 |
| GroupedDBID | --- --Z -DZ -ET -~X .-4 ..I .55 .DC 08G 0R~ 0WA 123 18M 2FS 2KS 2WC 2XV 34G 36B 39C 3R3 53G 5RE 66. 6OB 6TJ 7X2 7~K 85S 8F7 AABCJ AACGO AAIKC AAMNW AANCE AAWTO AAYXX ABCQX ABDBF ABDEX ABDQB ABEFU ABIVO ABJNI ABOCM ABPLY ABPPZ ABQIJ ABTLG ABWJO ABZEH ACBEA ACBEC ACGFO ACGFS ACGOD ACIWK ACMJI ACNCT ACPRK ACQOY ACUHS ADDRP ADUKH ADXHL AEGBM AENEX AETEA AFBNE AFFNX AFHKK AFQFN AFRAH AGFXO AGNAY AGSOS AHMBA AIDAL AIDUJ AJGZS ALIPV ALMA_UNASSIGNED_HOLDINGS ALSLI ASPBG AVWKF BKF BLC C45 CITATION CS3 DB2 DU5 EBS EMOBN F5P FA8 FEDTE HZ~ I.T IAO IEA IGS IH2 IHR INH INR IOF IOV IPO IPY ISE JCF JLS JSG JST K-O KCC L7B LSO LU7 M0P MQT MVM N9A NEJ NHB O9- OCB OFXIZ OGEVE OMK OVD P-O P2P PQQKQ PZZ RHI RXW SC5 SJN TAE TEORI TN5 TWZ UBW UCV UHB UKR UMD UNMZH UQL USG VVN WH7 WI4 X7M XJF XZL Y6R YK4 YKV YNT YOJ YR2 YR5 YRY YSQ YV5 YWH YYP YZZ ZCA ZE2 ~02 ~G0 ~KM ~ZZ CGR CUY CVF ECM EIF NPM 7QF 7QG 7QL 7QP 7QQ 7QR 7SC 7SE 7SN 7SP 7SR 7SS 7T7 7TA 7TB 7TK 7TM 7U5 7U9 8BQ 8FD C1K F28 FR3 H8D H8G H94 JG9 JQ2 K9. KR7 L7M L~C L~D M7N P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c515t-58d031a56a9a50c7673f5c0535780d5e1d960cc5bed7ba69ba1e08f8d9ad2a9d3 |
| ISSN | 0036-8075 1095-9203 |
| IngestDate | Thu Aug 21 13:46:28 EDT 2025 Fri Jul 11 15:54:16 EDT 2025 Fri Jul 25 19:21:14 EDT 2025 Mon Jul 21 06:03:06 EDT 2025 Tue Jul 01 01:35:35 EDT 2025 Thu Apr 24 23:05:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6561 |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c515t-58d031a56a9a50c7673f5c0535780d5e1d960cc5bed7ba69ba1e08f8d9ad2a9d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Author contributions: Conceptualization: NDR, AMcD, SEO, AP, MSS. Laboratory Investigation: SEO, LL, CAT, SDS, SO, WS, LW, BF, ESY. Laboratory Supervision: KC, BSG, JRM, NDR, AMcD, AP, MR, MSS. Clinical Investigation: LJ, EA, NGR, ATW, JEL, JA, BL, HB, CJL, PCR, PAR, MM, JHB, CAR. Writing, review and editing: NDR, SEO, AP, AMcD, LJ, EA, JEL, PCR, BL, LW, JRM, MSS, CJL, CAR. Statistical analysis: MCN. These authors contributed equally to this work. Present address: Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. |
| ORCID | 0000-0001-8112-0853 0000-0001-8439-0592 0000-0002-4452-141X 0000-0002-8404-4910 0000-0002-2512-7919 0000-0002-2641-4688 0000-0002-1785-0218 0000-0001-7615-8320 0000-0002-5293-4695 0000-0002-0110-881X 0000-0002-2686-8380 0000-0002-5731-3054 0000-0003-0616-9117 0000-0003-3564-6453 0000-0002-9808-063X 0000-0003-3161-1624 0000-0001-7448-7040 0000-0002-7284-3870 0000-0002-1576-4420 0000-0002-4879-4941 0000-0002-0313-8502 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8691522 |
| PMID | 34385356 |
| PQID | 2560879842 |
| PQPubID | 1256 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8691522 proquest_miscellaneous_2561485373 proquest_journals_2560879842 pubmed_primary_34385356 crossref_citationtrail_10_1126_science_abj4176 crossref_primary_10_1126_science_abj4176 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-09-17 |
| PublicationDateYYYYMMDD | 2021-09-17 |
| PublicationDate_xml | – month: 09 year: 2021 text: 2021-09-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Washington |
| PublicationTitle | Science (American Association for the Advancement of Science) |
| PublicationTitleAlternate | Science |
| PublicationYear | 2021 |
| Publisher | The American Association for the Advancement of Science |
| Publisher_xml | – name: The American Association for the Advancement of Science |
| References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_18_2 e_1_3_3_13_2 e_1_3_3_12_2 e_1_3_3_15_2 e_1_3_3_14_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_25_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_3_2 e_1_3_3_21_2 34031659 - bioRxiv. 2021 May 16:2021.05.13.444010. doi: 10.1101/2021.05.13.444010. |
| References_xml | – ident: e_1_3_3_12_2 doi: 10.1056/NEJMoa2101765 – ident: e_1_3_3_17_2 doi: 10.1056/NEJMoa2022483 – ident: e_1_3_3_29_2 doi: 10.1101/2021.05.05.21256716 – ident: e_1_3_3_18_2 doi: 10.1002/cpim.116 – ident: e_1_3_3_16_2 doi: 10.1056/NEJMoa2028436 – ident: e_1_3_3_20_2 doi: 10.1001/jama.2021.4388 – ident: e_1_3_3_23_2 doi: 10.1056/NEJMoa2035389 – ident: e_1_3_3_7_2 doi: 10.1038/s41591-021-01285-x – ident: e_1_3_3_25_2 doi: 10.1016/j.celrep.2021.109017 – ident: e_1_3_3_11_2 doi: 10.1056/NEJMc2104974 – ident: e_1_3_3_33_2 doi: 10.1038/s41422-021-00496-8 – ident: e_1_3_3_27_2 doi: 10.1016/j.smim.2018.10.010 – ident: e_1_3_3_28_2 doi: 10.1038/s41586-021-03696-9 – ident: e_1_3_3_24_2 doi: 10.1016/j.jbc.2021.100536 – ident: e_1_3_3_9_2 doi: 10.1056/NEJMc2108829 – ident: e_1_3_3_15_2 doi: 10.1056/NEJMc2032195 – ident: e_1_3_3_4_2 doi: 10.1016/j.cell.2021.03.036 – ident: e_1_3_3_8_2 doi: 10.1056/NEJMc2102179 – ident: e_1_3_3_21_2 doi: 10.1126/science.abh1766 – ident: e_1_3_3_2_2 – ident: e_1_3_3_3_2 doi: 10.1016/j.chom.2021.03.009 – ident: e_1_3_3_6_2 doi: 10.1038/s41586-021-03398-2 – ident: e_1_3_3_32_2 doi: 10.1371/journal.pntd.0006862 – ident: e_1_3_3_5_2 doi: 10.1056/NEJMc2103740 – ident: e_1_3_3_19_2 doi: 10.1016/j.chom.2020.11.012 – ident: e_1_3_3_26_2 doi: 10.1101/2021.02.18.431897 – ident: e_1_3_3_30_2 doi: 10.1073/pnas.93.21.11382 – ident: e_1_3_3_10_2 doi: 10.1056/NEJMoa2001017 – ident: e_1_3_3_14_2 doi: 10.1056/NEJMc2103916 – ident: e_1_3_3_22_2 doi: 10.1126/science.abb2507 – ident: e_1_3_3_13_2 doi: 10.1016/S0140-6736(21)01358-1 – ident: e_1_3_3_31_2 doi: 10.1128/JVI.01118-06 – reference: 34031659 - bioRxiv. 2021 May 16:2021.05.13.444010. doi: 10.1101/2021.05.13.444010. |
| SSID | ssj0009593 |
| Score | 2.717184 |
| Snippet | The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern poses a potential obstacle to achieving vaccine-induced... Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody... A boost for boostersThe evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern poses a potential obstacle to achieving... SARS-CoV-2 mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the impact of... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1372 |
| SubjectTerms | 2019-nCoV Vaccine mRNA-1273 ACE2 Adolescent Adult Aged Angiotensin Angiotensin-converting enzyme 2 Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Binding Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Cross Reactions Feedback (Response) Health policy Humans Immune Evasion Immune response Immune system Immunization, Secondary Immunogenicity, Vaccine Medical research Middle Aged mRNA Mutation Neutralizing Peptidyl-dipeptidase A Public health Respiratory diseases SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Time Factors Vaccines Viral diseases Young Adult |
| Title | Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34385356 https://www.proquest.com/docview/2560879842 https://www.proquest.com/docview/2561485373 https://pubmed.ncbi.nlm.nih.gov/PMC8691522 |
| Volume | 373 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZy2AvZe1u2bqhwR46goIvkiU_updQRsigTUbejGzLXcYajzYudL9-R5Z8SZpBtxcTLMlydI6OvyMdfQehTxJmAZWZIEzlHqGKhkQqnhH4NlMFTQKVVGyfk-B8Rr_M2bzXu-9ELZWrZJj-3nqu5H-kCvdArvqU7D9Itnko3IDfIF-4goTh-igZn5Y3hmbbbJNfTCLiAlAY3MlU75cT8LdLvb8Po7dICh0vOJBXcgGIcHAZXVySk-Ib8aA2vKpldKpxaj3lAX82ezodSTbBiZEJIagjCmyz7uLtejBNtQDdnn4Ym2TYY_gPjZJGmnXL7JAsrttViqxyDSrTfWc12i5WeK6OrDBnM619dXRqSM8xNk1tuWeNsm8SnFjtA9Dpdqys65t0Pw_NfydhpRrK5Ad1-Rai7cnXeDQbj-Pp2Xz6BO164GGAidyNjk-PR5uMzc3bWV6ozomruoN1SPPAT9kMt-3gl-lztGcdDxwZLdpHPbU8QE9NKtL7A7RvRXeLjywT-ecXaNIqGC5y3CgY3lAw3CoYtgqGWwXDtYK9RLPR2fTknNgEHCQFmLsiTGRg8yULZCiZk_KA-zlLNSMQF07GlJuB_5umLFEZT2QQJtJVjshFFsrMk2Hmv0I7y2Kp3iDMc1_lOXPBZHCa8FwEwgmUkCylQqqc9dGwHsM4tez0OknKz7jyUr0gtoMe20Hvo6OmwS9DzPL3qoe1UGI7e29jDfUFDwX1-uhjUwy2VW-YyaUqyqqOSwHPcr-PXhsZNn351IcSBg_na9JtKmje9vWS5eJ7xd8ughBQs_f2Ef2-Q8_aaXSIdlY3pXoPKHiVfLD6-gfaQbWj |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Durability+of+mRNA-1273+vaccine-induced+antibodies+against+SARS-CoV-2+variants&rft.jtitle=Science+%28American+Association+for+the+Advancement+of+Science%29&rft.au=O%27Connell%2C+Sarah+E&rft.au=Lai%2C+Lilin&rft.au=Albert%2C+Jim&rft.au=Anderson%2C+Evan&rft.date=2021-09-17&rft.issn=1095-9203&rft.eissn=1095-9203&rft.volume=373&rft.issue=6561&rft.spage=1372&rft_id=info:doi/10.1126%2Fscience.abj4176&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0036-8075&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0036-8075&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0036-8075&client=summon |